After a verbal offer to buy out OSI Pharmaceuticals Inc. for $52 per share - about $3.5 billion - failed to entice the company's board last month, Astellas Pharma Inc. is taking its bid straight to shareholders but may have to up its price to get the deal done. (BioWorld Today) Read More
